FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Identifying the Conditions Under Which Antibodies Protect Ag...
Vaccines2014; 2(2); 397-421; doi: 10.3390/vaccines2020397

Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.

Abstract: The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV infection in SCID horses may lead to insights into the mechanisms of control of infection by antibody vaccination. In this work, such a model is constructed in conjunction with data from EIAV infection of SCID horses to gain insights into multiple strain competition in the presence of antibody control. Conditions are determined under which wild-type infection is eradicated with the antibody vaccine. In addition, a three-strain competition model is considered in which a second mutant strain may coexist with the first mutant strain. The conditions that permit viral escape by the mutant strains are determined, as are the effects of variation in the model parameters. This work extends the current understanding of competition and antibody control in lentiviral infection, which may provide insights into the development of vaccines that stimulate the immune system to control infection effectively.
Get Full Text
Publication Date: 2014-05-27 PubMed ID: 26344625PubMed Central: PMC4494265DOI: 10.3390/vaccines2020397Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The researchers developed a model to understand how antibodies assist in combating the equine infectious anemia virus (EIAV). They focused on looking at the variables that allow the successful eradication of the wild-type virus using an antibody vaccine, the conditions that facilitate virus escape by mutant strains, and the impact of these model’s variable changes.

Purpose of the Research

  • The primary aim of this research was to better understand and predict the conditions under which antibodies can be protective against viral infection. This outcome could potentially transform vaccine development practices.
  • As part of this aim, the researchers wanted to delve deeper into how antibodies protect against lentivirus infections and the role of viral mutations in resistance to an antibody-based vaccine.

Methodology and Insights

  • A specific case of antibody-mediated vaccine protection was examined; the transfer of neutralizing antibodies before EIAV infection of horses with severe combined immunodeficiency (SCID). The researchers utilized data from this case to model the dynamics of the virus and observe under what conditions antibody protection exerts control over the virus.
  • Their model also allowed for the exploration of multiple strain competitions in the presence of antibody control. This angle is crucial as it reflects the reality that many viruses, including EIAV, can exist in multiple strains.

Findings

  • By applying their model, the researchers were able to identify the conditions under which an antibody vaccine eradicates the standard or wild-type infection.
  • Considering infections with more complexity, such as those involving multiple dynamic strains, they determined the circumstances that facilitate the escape of mutant viral strains. Essentially, the model allowed them to understand when and how a virus can evade control measures exerted by an antibody vaccine.
  • Furthermore, they were able to observe the effects of variabilities in different parameters of the model, providing a richer understanding of the factors influencing the interaction between the virus and the antibody vaccine.

Implications and Future Research

  • This study broadens our understanding of the interaction between antibodies and viral infections, particularly in terms of competition and control in lentiviral infections.
  • These findings may aid in the development of vaccines that better stimulate the immune system, leading to more effective control of viral infections. However, as this work centered on a model and data from EIAV in SCID horses, further research and testing in other organisms and viruses are necessary to validate and build upon these findings.

Cite This Article

APA
Schwartz EJ, Smith RJ. (2014). Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus. Vaccines (Basel), 2(2), 397-421. https://doi.org/10.3390/vaccines2020397

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 2
Issue: 2
Pages: 397-421

Researcher Affiliations

Schwartz, Elissa J
  • School of Biological Sciences and Department of Mathematics, Washington State University, Pullman, WA 99164, USA. ejs@wsu.edu.
Smith, Robert J
  • Department of Mathematics and Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada. rsmith43@uottawa.ca.

References

This article includes 47 references
  1. Liu P, Overman RG, Yates NL, Alam SM, Vandergrift N, Chen Y, Graw F, Freel SA, Kappes JC, Ochsenbauer C, Montefiori DC, Gao F, Perelson AS, Cohen MS, Haynes BF, Tomaras GD. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.. J Virol 2011 Nov;85(21):11196-207.
    doi: 10.1128/JVI.05601-11pmc: PMC3194959pubmed: 21865397google scholar: lookup
  2. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.. J Virol 2008 Dec;82(24):12449-63.
    doi: 10.1128/JVI.01708-08pmc: PMC2593361pubmed: 18842730google scholar: lookup
  3. Leroux C, Cadoré JL, Montelaro RC. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?. Vet Res 2004 Jul-Aug;35(4):485-512.
    doi: 10.1051/vetres:2004020pubmed: 15236678google scholar: lookup
  4. Maury W, Oaks JL. Equine infectious anemia virus pathogenesis and replication.. .
  5. Mealey RH, Fraser DG, Oaks JL, Cantor GH, McGuire TC. Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses.. Clin Immunol 2001 Nov;101(2):237-47.
    doi: 10.1006/clim.2001.5109pmc: PMC3342689pubmed: 11683583google scholar: lookup
  6. Perryman LE, O'Rourke KI, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.. J Virol 1988 Aug;62(8):3073-6.
    pmc: PMC253753pubmed: 2839723doi: 10.1128/jvi.62.8.3073-3076.1988google scholar: lookup
  7. Carpenter S, Chen WC, Dorman KS. Rev variation during persistent lentivirus infection.. Viruses 2011 Jan;3(1):1-11.
    doi: 10.3390/v3010001pmc: PMC3187595pubmed: 21994723google scholar: lookup
  8. Mealey RH, Leib SR, Littke MH, Wagner B, Horohov DW, McGuire TC. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.. Vaccine 2009 Apr 21;27(18):2453-68.
    doi: 10.1016/j.vaccine.2009.02.048pmc: PMC2773546pubmed: 19368787google scholar: lookup
  9. Wu W, Blythe DC, Loyd H, Mealey RH, Tallmadge RL, Dorman KS, Carpenter S. Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.. J Virol 2011 Oct;85(19):10421-4.
    doi: 10.1128/JVI.05349-11pmc: PMC3196457pubmed: 21752904google scholar: lookup
  10. Taylor SD, Leib SR, Carpenter S, Mealey RH. Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.. J Virol 2010 Jul;84(13):6536-48.
    doi: 10.1128/JVI.00218-10pmc: PMC2903280pubmed: 20392850google scholar: lookup
  11. Taylor SD, Leib SR, Wu W, Nelson R, Carpenter S, Mealey RH. Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.. J Virol 2011 Jul;85(13):6814-8.
    doi: 10.1128/JVI.00077-11pmc: PMC3126505pubmed: 21543497google scholar: lookup
  12. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.. J Virol 1999 May;73(5):4009-18.
    pmc: PMC104180pubmed: 10196297doi: 10.1128/jvi.73.5.4009-4018.1999google scholar: lookup
  13. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.. Nat Med 2010 Oct;16(10):1117-9.
    doi: 10.1038/nm.2233pmc: PMC2952052pubmed: 20890292google scholar: lookup
  14. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.. Proc Natl Acad Sci U S A 2003 Dec 9;100(25):15131-6.
    doi: 10.1073/pnas.2436476100pmc: PMC299920pubmed: 14627745google scholar: lookup
  15. Ruprecht RM, Ferrantelli F, Kitabwalla M, Xu W, McClure HM. Antibody protection: Passive immunization of neonates against oral AIDS virus challenge.. Methods Mol. Biol. 2009;525:559–566.
    pubmed: 0
  16. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.. Nat Med 1999 Feb;5(2):204-10.
    doi: 10.1038/5568pubmed: 9930869google scholar: lookup
  17. Schwartz EJ, Pawelek KA, Harrington K, Cangelosi R, Madrid S. Immune control of equine infectious anemia virus infection by CTLs and antibodies.. Appl. Math. 2013;4:171–177.
    doi: 10.4236/am.2013.48A023google scholar: lookup
  18. Ciupe SM, Schwartz EJ. Understanding virus-host dynamics following EIAV infection in SCID horses.. J Theor Biol 2014 Feb 21;343:1-8.
    doi: 10.1016/j.jtbi.2013.11.003pubmed: 24252283google scholar: lookup
  19. Smith RJ, Schwartz EJ. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?. Math Biosci 2008 Apr;212(2):180-7.
    doi: 10.1016/j.mbs.2008.02.001pubmed: 18359048google scholar: lookup
  20. Konrad BP, Vaidya NK, Smith RJ. Modelling mutation to a cytotoxic T-lymphocyte HIV vaccine.. Math. Pop. Stud. 2011;18:122–149.
  21. Bainov DD, Simeonov PS. Systems with Impulsive Effect.. .
  22. Bainov DD, Simeonov PS. Impulsive differential equations: Periodic solutions and applications.. .
  23. Bainov DD, Simeonov PS. Impulsive Differential Equations: Asymptotic Properties of the Solutions.. .
  24. Lakshmikantham V, Bainov DD, Simeonov PS. Theory of Impulsive Differential Equations.. .
  25. Agur Z, Cojocaru L, Mazor G, Anderson RM, Danon YL. Pulse mass measles vaccination across age cohorts.. Proc Natl Acad Sci U S A 1993 Dec 15;90(24):11698-702.
    doi: 10.1073/pnas.90.24.11698pmc: PMC48051pubmed: 8265611google scholar: lookup
  26. Stone L, Olinky R, Huppert A. Seasonal dynamics of recurrent epidemics.. Nature 2007 Mar 29;446(7135):533-6.
    doi: 10.1038/nature05638pubmed: 17392785google scholar: lookup
  27. Miron RE, Smith RJ. Modelling imperfect adherence to HIV induction therapy.. BMC Infect Dis 2010 Jan 12;10:6.
    doi: 10.1186/1471-2334-10-6pmc: PMC2833165pubmed: 20064271google scholar: lookup
  28. Roberts MG, Kao RR. The dynamics of an infectious disease in a population with birth pulses.. Math Biosci 1998 Apr;149(1):23-36.
    doi: 10.1016/S0025-5564(97)10016-5pubmed: 9610109google scholar: lookup
  29. Al-arydah M, Smith RJ, Lutscher F. Modelling gender-structured wildlife diseases with harvesting: Chronic Wasting Disease as an example.. ISRN Biomath 2012;2012.
    doi: 10.5402/2012/802450google scholar: lookup
  30. Kot M. Elements of Mathematical Ecology.. .
  31. Schwartz EJ, Neumann AU, Teixeira AV, Bruggeman LA, Rappaport J, Perelson AS, Klotman PE. Effect of target cell availability on HIV-1 production in vitro.. AIDS 2002 Feb 15;16(3):341-5.
    doi: 10.1097/00002030-200202150-00004pubmed: 11834944google scholar: lookup
  32. Waldmann TA, Strober W. Metabolism of immunoglobulins.. Prog Allergy 1969;13:1-110.
    pubmed: 4186070doi: 10.1159/000385919google scholar: lookup
  33. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, Perelson AS, Marx PA, Ho DD, Kostrikis LG, Connor RI. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.. J Exp Med 2000 Jun 5;191(11):1921-31.
    doi: 10.1084/jem.191.11.1921pmc: PMC2213531pubmed: 10839807google scholar: lookup
  34. Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, Kinter A, Fauci AS, Hirsch VM, Lifson JD. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.. J Virol 1997 Oct;71(10):7518-25.
    pmc: PMC192098pubmed: 9311831doi: 10.1128/jvi.71.10.7518-7525.1997google scholar: lookup
  35. Van Rompay KK, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.. J Virol 2004 May;78(10):5324-37.
    doi: 10.1128/JVI.78.10.5324-5337.2004pmc: PMC400346pubmed: 15113912google scholar: lookup
  36. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.. J Virol 1995 Aug;69(8):5087-94.
    pmc: PMC189326pubmed: 7541846doi: 10.1128/jvi.69.8.5087-5094.1995google scholar: lookup
  37. BRYAN WR. Interpretation of host response in quantitative studies on animal viruses.. Ann N Y Acad Sci 1957 Dec 16;69(4):698-728.
    doi: 10.1111/j.1749-6632.1957.tb49710.xpubmed: 13488325google scholar: lookup
  38. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.. Lancet 1999 Nov 20;354(9192):1782-5.
    doi: 10.1016/S0140-6736(99)02035-8pubmed: 10577640google scholar: lookup
  39. Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio.. J R Soc Interface 2005 Sep 22;2(4):281-93.
    doi: 10.1098/rsif.2005.0042pmc: PMC1578275pubmed: 16849186google scholar: lookup
  40. Schwartz EJ, Vaidya NK, Dorman KS, Carpenter S, Mealey RH. Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses.. Virology 2018 Jan 1;513:108-113.
    pubmed: 29055819doi: 10.1016/j.virol.2017.09.023google scholar: lookup
  41. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example.. Int. Stat. Rev. 1994;2:229–243.
    doi: 10.2307/1403510google scholar: lookup
  42. Schwartz EJ, Blower S. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines.. J Infect Dis 2005 May 15;191(10):1734-46.
    doi: 10.1086/429299pubmed: 15838802google scholar: lookup
  43. Schwartz EJ, Bodine EN, Blower S. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines.. Hum Vaccin 2007 Nov-Dec;3(6):231-8.
    doi: 10.4161/hv.4529pubmed: 17881889google scholar: lookup
  44. Smith RJ, Cloutier P, Harrison J, Desforges A. A mathematical model for the eradication of Guinea Worm Disease.. .
  45. Schwartz EJ, Nanda S. Antibody Escape Kinetics of EIAV Infection of Horses.. J. Virol. 2014 submitted for publication.
  46. Tschetter JR, Byrne KM, Perryman LE, McGuire TC. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies.. Virology 1997 Apr 14;230(2):275-80.
    doi: 10.1006/viro.1997.8502pubmed: 9143283google scholar: lookup
  47. Li J, Blakeley D, Smith RJ. The failure of R0.. Comput Math Methods Med 2011;2011:527610.
    doi: 10.1155/2011/527610pmc: PMC3157160pubmed: 21860658google scholar: lookup

Citations

This article has been cited 3 times.
  1. Hull-Nye D, Meadows T, Smith SR, Schwartz EJ. Key Factors and Parameter Ranges for Immune Control of Equine Infectious Anemia Virus Infection. Viruses 2023 Mar 6;15(3).
    doi: 10.3390/v15030691pubmed: 36992401google scholar: lookup
  2. Schwartz EJ, Costris-Vas C, Smith SR. Modelling Mutation in Equine Infectious Anemia Virus Infection Suggests a Path to Viral Clearance with Repeated Vaccination. Viruses 2021 Dec 6;13(12).
    doi: 10.3390/v13122450pubmed: 34960718google scholar: lookup
  3. Song Q, Stone S, Drebes D, Greiner LL, Dvorak CMT, Murtaugh MP. Characterization of anti-porcine epidemic diarrhea virus neutralizing activity in mammary secretions. Virus Res 2016 Dec 2;226:85-92.
    doi: 10.1016/j.virusres.2016.06.002pubmed: 27287711google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.